Philadelphia University + Thomas Jefferson University
Sidney Kimmel Medical College
Department of Medicine

Duffy, Danielle

< Back

Profile

noimage

Danielle Duffy, MD

Contact Dr. Duffy

925 Chestnut Street
Mezzanine Level
Philadelphia, PA 19107

(215) 955-3607
(215) 503-3976 fax

Medical School

University of Pennsylvania School of Medicine - 2002

Residency

Hospital of the University of Pennsylvania

Fellowship

University of Pennsylvania School of Medicine
Cardiovascular Diseases, Thomas Jefferson University Hospital

Board Certification

Internal Medicine
Cardiovascular Disease

Hospital Appointment

Thomas Jefferson University Hospital

Expertise & Research Areas

My areas of clinical expertise are complex lipid disorders, cardiovascular prevention, and cardiovascular disease in women. My general research focus is preventive cardiology. My specific interests and ongoing projects involve new therapeutics for HDL and LDL-cholesterol, the use of additional diagnostic testing for cardiovascular risk stratification, and women's cardiovascular prevention.

Keywords

Lipid disorders; preventive cardiology; familial hypercholesterolemia; new therapeutics; women's cardiovascular health

Publications

Most Recent Peer-Reviewed Publications

  1. Pharmacokinetics and Safety of CSL112 (Apolipoprotein A-I [Human]) in Adults With Moderate Renal Impairment and Normal Renal Function
  2. Moderate Renal Impairment Does Not Impact the Ability of CSL112 (Apolipoprotein A-I [Human]) to Enhance Cholesterol Efflux Capacity
  3. The CSL112-2001 trial: Safety and tolerability of multiple doses of CSL112 (apolipoprotein A-I [human]), an intravenous formulation of plasma-derived apolipoprotein A-I, among subjects with moderate renal impairment after acute myocardial infarction
  4. Health disparities among adult patients with a phenotypic diagnosis of familial hypercholesterolemia in the CASCADE-FH™ patient registry
  5. Oral Apolipoprotein A-I Mimetic D-4F Lowers HDL-Inflammatory Index in High-Risk Patients: A First-in-Human Multiple-Dose, Randomized Controlled Trial
  6. Impact of the 2013 American College of Cardiology/American Heart Association cholesterol guidelines on the prescription of high-intensity statins in patients hospitalized for acute coronary syndrome or stroke
  7. US physician practices for diagnosing familial hypercholesterolemia: data from the CASCADE-FH registry
  8. Treatment gaps in adults with heterozygous familial hypercholesterolemia in the United States
  9. Pharmacogenetics in the Development of Lipid Lowering Medications: Lomitapide & Mipomersen in Clinical Practice
  10. 2013 ACC/AHA cholesterol treatment guideline: Paradigm shifts in managing atherosclerotic cardiovascular disease risk
  11. Targeting Lipoprotein (a): an Evolving Therapeutic Landscape
  12. Modeled risk of ischemic heart disease following left breast irradiation with deep inspiration breath hold
  13. PA32540 for the secondary prevention of cardiovascular disease in patients at risk for aspirin-associated gastric ulcers
  14. Novel treatments for familial hypercholesterolemia: Pharmacogenetics at work
  15. Aspirin for cardioprotection and strategies to improve patient adherence
  16. Pharmacokinetic interactions of the microsomal triglyceride transfer protein inhibitor, lomitapide, with drugs commonly used in the management of hypercholesterolemia
  17. The impact of high-density lipoprotein cholesterol levels on long-term outcomes after non-ST-elevation myocardial infarction
  18. Potent and selective PPAR-α agonist LY518674 upregulates both apoA-I production and catabolism in human subjects with the metabolic syndrome
  19. Update on strategies to increase hdl quantity and function
  20. Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patients